0001387131-20-005871.txt : 20200622 0001387131-20-005871.hdr.sgml : 20200622 20200622172913 ACCESSION NUMBER: 0001387131-20-005871 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200622 FILED AS OF DATE: 20200622 DATE AS OF CHANGE: 20200622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36033 FILM NUMBER: 20979719 BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Theravance Biopharma, Inc. CENTRAL INDEX KEY: 0001583107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 BUSINESS PHONE: 650-808-6000 MAIL ADDRESS: STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 4 1 tbph-form4_062220.xml OWNERSHIP DOCUMENT X0306 4 2020-06-22 0 0001583107 Theravance Biopharma, Inc. TBPH 0001131399 GLAXOSMITHKLINE PLC 980 GREAT WEST ROAD BRENTFORD MIDDLESEX X0 TW8 9GS UNITED KINGDOM 0 0 1 0 Exchangeable Note 29.0660 2020-06-22 4 S 0 280336000 D Ordinary Shares 9644792 0 I See Footnote On June 22, 2020, GSK Finance No.3 plc ("GSK Finance"), a wholly owned indirect subsidiary of GlaxoSmithKline plc ("GSK"), issued $280,336,000 of its senior notes due 2023 (the "Notes") exchangeable into ordinary shares ("Ordinary Shares") of Theravance Biopharma, Inc. ("Theravance Biopharma"). The Ordinary Shares are held directly by GSK Finance. The Notes are guaranteed by GSK and exchangeable at the option of noteholders on any business day on or after September 1, 2020 for up to 9,644,792 Ordinary Shares at an initial exchange rate of 34.4044 Ordinary Shares per $1,000 principal amount of Notes, which is equivalent to an initial exchange price of approximately $29.0660. Under certain circumstances, GSK Finance may deliver cash in lieu of Ordinary Shares or a combination of Ordinary Shares and cash. The sale of the Notes resulted in $304,164,560 of gross proceeds. /s/ Victoria Whyte 2020-06-22